Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
These results support that gabapentin decreases hot flashes, to a moderate degree, in men with androgen ablation-related vasomotor dysfunction. To obtain pilot prospective data regarding the efficacy and tolerability of gabapentin for alleviating hot flashes. Pilot studies for the antidepressants venlafaxine and paroxetine suggested they may be useful for men having hot flashes in androgen deprived states (Loprinzi et al., PMID 15473404 and Quella et al., PMID 10379749). One placebo controlled trial evaluating venlafaxine and a soy protein showed more su The best way to relieve hot flashes is to take estrogen. But taking this hormone carries risks. If estrogen is right for you and you start it within 10 years of your last menstrual period or before age 60, the plusses can be greater than the risks. Medicines such as antidepressants and anti-seizure medicines also might help ease hot flashes. But they don't work as well as hormones do. Talk to Hot flashes are a complication of androgen deprivation therapy given to men with prostate cancer. A previous clinical study indicated that use of low dose gabapentin (900mg/day) was well-tolerated and decreased hot flash frequency to a moderate A patient with prostate cancer and debilitating hot flashes and night sweats had nearly complete relief of symptoms with oxybutynin. Further studies are warranted. It is suggested that low-dose gabapentin is moderately efficacious for at least 12 weeks of hot flash treatment in men undergoing androgen deprivation therapy for prostate cancer and seems to be well tolerated. Hot flashes are a complication of androgen deprivation therapy for prostate cancer. A phase III study showed that use of low-dose gabapentin was well tolerated and moderately decreased Via a prospective, double-blind, placebo-controlled clinical trial, men with hot flashes, on a stable androgen deprivation therapy program for prostate cancer, received a placebo or gabapentin at target doses of 300, 600, or 900 mg/day. Hot flash frequencies and severities were recorded daily during a baseline week and for 4 weeks while the patients took the study medication. Introduction: Hot flashes represent a significant problem in men undergoing androgen deprivation therapy. Materials and methods: Via a prospective, double-blind, placebo-controlled clinical trial, men with hot flashes, on a stable androgen deprivation therapy program for prostate cancer, received a placebo or gabapentin at target doses of 300, 600, or 900 mg/day. Hot flash frequencies and Background: Hot flashes are a common, undesirable complication of androgen-deprivation therapy in men with prostate cancer. A previous randomized trial indicated that gabapentin (900 mg/day) was well-tolerated and moderately decreased hot flashes for 4 weeks, leading to increased quality of life and satisfaction with hot flash control (Loprinzi et al; Ann Oncol 2009, 20; 542-9). Men can experience the discomfort of hot flashes just as menopausal women do. Learn about symptoms, causes, and treatment. Hot flashes are one of the most common symptoms of menopause, affecting a significant number of women. While hormone therapy (HT) has traditionally been the primary treatment for this symptom, concerns about its long-term safety have led many to seek non-hormonal alternatives. Gabapentin, primarily known for its use in treating neuropathic pain and as an anticonvulsant, emerges as a promising Abstract Introduction: Hot flashes represent a significant problem in men undergoing androgen deprivation therapy. Materials and methods: Via a prospective, double-blind, placebo-controlled clinical trial, men with hot flashes, on a stable androgen deprivation therapy program for prostate cancer, received a placebo or gabapentin at target doses of 300, 600, or 900 mg/day. Hot flash frequencies Request PDF | Gabapentin for hot flashes in men: NCCTG trial N00CB | 9005 Background: Hot flashes can be a major problem in men with prostate cancer; effective non-hormonal options are needed The gabapentin was remarkably well tolerated, without any statistically significantly worse patient-reported side effects on the gabapentin arms. Conclusion: Gabapentin at the 900 mg/d dose can reduce hot flashes, in men receiving androgen deprivation therapy for prostate cancer. No significant financial relationships to disclose. Article abstract The author describes six cases in which gabapentin treatment reduced the frequency of hot flashes. In addition, gabapentin treatment enhanced the frequency of hypothermic episodes in a separate patient with known hypothalamic Via a prospective, double-blind, placebo-controlled clinical trial, men with hot flashes, on a stable androgen deprivation therapy program for prostate cancer, received a placebo or gabapentin at target doses of 300, 600, or 900 mg/day. Hot flash frequencies and severities were recorded daily during a baseline week and for 4 weeks while the patients took the study medication. A small phase III, randomized, double blind, placebo controlled trial of Gabapentin which looked at the Management of hot flashes in men on a hormone blockade (ADT) was recently completed and published in the March 2009 journal of the Ann of Oncology. One of the most common and bothersome side effects of a hormone Hot flashes may last for 30 seconds or 5 minutes, with an average of approximately 4 minutes. 5 The frequency and severity may wax and wane in the same individual in response to unknown environmental and physiologic influences. Hot flashes result from estrogen withdrawal and occur in both men and women. Hot flashes resulting from ADT can be an extremely bothersome adverse effect in men with prostate cancer. Agents such as medroxyprogesterone, gabapentin, venlafaxine and acupuncture have shown
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |